140 related articles for article (PubMed ID: 7871992)
21. Immobilization hypercalcemia associated with Landry-Guillain-Barré syndrome. Successful therapy with combined calcitonin and etidronate.
Meythaler JM; Korkor AB; Nanda T; Kumar NA; Fallon M
Arch Intern Med; 1986 Aug; 146(8):1567-71. PubMed ID: 3089187
[TBL] [Abstract][Full Text] [Related]
22. Persistent hypercalciuria and elevated 25-hydroxyvitamin D3 in children with infantile hypercalcaemia.
Pronicka E; Rowińska E; Kulczycka H; Lukaszkiewicz J; Lorenc R; Janas R
Pediatr Nephrol; 1997 Feb; 11(1):2-6. PubMed ID: 9035162
[TBL] [Abstract][Full Text] [Related]
23. Loss-of-function mutations of CYP24A1, the vitamin D 24-hydroxylase gene, cause long-standing hypercalciuric nephrolithiasis and nephrocalcinosis.
Dinour D; Beckerman P; Ganon L; Tordjman K; Eisenstein Z; Holtzman EJ
J Urol; 2013 Aug; 190(2):552-7. PubMed ID: 23470222
[TBL] [Abstract][Full Text] [Related]
24. Calcitonin therapy in prolonged immobilization hypercalcemia.
Carey DE; Raisz LG
Arch Phys Med Rehabil; 1985 Sep; 66(9):640-4. PubMed ID: 4038033
[TBL] [Abstract][Full Text] [Related]
25. Calcium and bone homeostasis in heterozygous carriers of CYP24A1 mutations: A cross-sectional study.
Cools M; Goemaere S; Baetens D; Raes A; Desloovere A; Kaufman JM; De Schepper J; Jans I; Vanderschueren D; Billen J; De Baere E; Fiers T; Bouillon R
Bone; 2015 Dec; 81():89-96. PubMed ID: 26117226
[TBL] [Abstract][Full Text] [Related]
26. Effect of 24,25-dihydroxyvitamin D3 on 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] metabolism in vitamin D-deficient rats infused with 1,25-(OH)2D3.
Yamato H; Matsumoto T; Fukumoto S; Ikeda K; Ishizuka S; Ogata E
Endocrinology; 1989 Jan; 124(1):511-7. PubMed ID: 2783309
[TBL] [Abstract][Full Text] [Related]
27. Progressively increased serum 1,25-dihydroxyvitamin D2 concentration in a hypoparathyroid patient with protracted hypercalcemia due to vitamin D2 intoxication.
Sato K; Emoto N; Toraya S; Tsushima T; Demura H; Tsuji N; Inaba S; Takeuchi A; Kobayashi T
Endocr J; 1994 Aug; 41(4):329-37. PubMed ID: 8528347
[TBL] [Abstract][Full Text] [Related]
28. Juvenile onset IIH and
Schlingmann KP; Cassar W; Konrad M
Bone Rep; 2018 Dec; 9():42-46. PubMed ID: 30591926
[TBL] [Abstract][Full Text] [Related]
29. Familial occurrence of idiopathic infantile hypercalcemia.
McTaggart SJ; Craig J; MacMillan J; Burke JR
Pediatr Nephrol; 1999 Oct; 13(8):668-71. PubMed ID: 10502124
[TBL] [Abstract][Full Text] [Related]
30. Nephrocalcinosis in a 2-month-old girl suffering from a mild variant of idiopathic infantile hypercalcemia.
Zajadacz B; Juszkiewicz A
Wiad Lek; 2004; 57(11-12):710-2. PubMed ID: 15865256
[TBL] [Abstract][Full Text] [Related]
31. A rapid screening of a recurrent CYP24A1 pathogenic variant opens the way to molecular testing for Idiopathic Infantile Hypercalcemia (IIH).
De Paolis E; Minucci A; De Bonis M; Scaglione GL; Gervasoni J; Primiano A; Ferraro PM; Cappellani D; Marcocci C; Gambaro G; Capoluongo E
Clin Chim Acta; 2018 Jul; 482():8-13. PubMed ID: 29574006
[TBL] [Abstract][Full Text] [Related]
32. Symptomatic hypercalcemia in the first months of life: calcium-regulating hormones and treatment.
Ghirri P; Bottone U; Coccoli L; Bernardini M; Vuerich M; Cuttano A; Riparbelli C; Pellegrinetti G; Boldrini A
J Endocrinol Invest; 1999 May; 22(5):349-53. PubMed ID: 10401708
[TBL] [Abstract][Full Text] [Related]
33. Vitamin D3 analogs and salmon calcitonin partially reverse the development of renal osteodystrophy in rats.
Jablonski G; Mortensen BM; Klem KH; Mosekilde L; Danielsen CC; Gordeladze JO
Calcif Tissue Int; 1995 Nov; 57(5):385-91. PubMed ID: 8564802
[TBL] [Abstract][Full Text] [Related]
34. CYP24A1 Mutation in a Girl Infant with Idiopathic Infantile Hypercalcemia.
Madsen JOB; Sauer S; Beck B; Johannesen J
J Clin Res Pediatr Endocrinol; 2018 Mar; 10(1):83-86. PubMed ID: 28874334
[TBL] [Abstract][Full Text] [Related]
35. Pamidronate and calcitonin as therapy of acute cancer-related hypercalcemia in children.
Schmid I; Stachel D; Schön C; Bauer M; Haas RJ
Klin Padiatr; 2001; 213(1):30-4. PubMed ID: 11225473
[TBL] [Abstract][Full Text] [Related]
36. Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment.
Tebben PJ; Singh RJ; Kumar R
Endocr Rev; 2016 Oct; 37(5):521-547. PubMed ID: 27588937
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of salmon calcitonin administered as suppositories in tumor-induced hypercalcemia.
Thiébaud D; Burckhardt P; Jaeger P; Azria M
Am J Med; 1987 Apr; 82(4):745-50. PubMed ID: 3565431
[TBL] [Abstract][Full Text] [Related]
38. Effect of the X-linked Hyp mutation and vitamin D status on induction of renal 25-hydroxyvitamin D3-24-hydroxylase.
Tenenhouse HS; Jones G
Endocrinology; 1987 Feb; 120(2):609-16. PubMed ID: 3803293
[TBL] [Abstract][Full Text] [Related]
39. Dose-response effects of supplementation with calcifediol on serum 25-hydroxyvitamin D status and its metabolites: A randomized controlled trial in older adults.
Vaes AMM; Tieland M; de Regt MF; Wittwer J; van Loon LJC; de Groot LCPGM
Clin Nutr; 2018 Jun; 37(3):808-814. PubMed ID: 28433267
[TBL] [Abstract][Full Text] [Related]
40. Effect of calcitonin and glutocorticoids in combination on the hypercalcemia of malignancy.
Binstock ML; Mundy GR
Ann Intern Med; 1980 Aug; 93(2):269-72. PubMed ID: 7406378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
